LOGIN  |  REGISTER
Assertio
Viking Therapeutics

Travere Therapeutics to Participate at Upcoming Investor Conferences

August 05, 2025 | Last Trade: US$36.26 0.00 0.00

SAN DIEGO / Aug 05, 2025 / Business Wire / Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will participate in the following upcoming investor conferences:

Canaccord Genuity 45th Annual Growth Conference
Presenting on Wednesday, August 13, 2025, at 8:00 a.m. ET

Citi's 2025 Biopharma Back to School Conference
Presenting on Tuesday, September 2, 2025, at 3:15 p.m. ET

2025 Wells Fargo Healthcare Conference
Presenting on Wednesday, September 3, 2025, at 1:30 p.m. ET

Cantor Global Healthcare Conference 2025
Presenting on Thursday, September 4, 2025, at 2:45 p.m. ET

Live webcasts of the presentations will be accessible on the Investor page of Travere’s website at ir.travere.com/events-and-presentations. Replays will be available for up to 30 days following each event.

About Travere Therapeutics

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit www.travere.com

Viking Therapeutics

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page